Literature DB >> 25029933

Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.

Emmanouil Panagiotidis1, Jamshed Bomanji2.   

Abstract

The most widely used PET radiopharmaceutical in daily clinical practice is (18)F-fluorodeoxyglucose (FDG). The evaluation of glycolytic metabolism by (18)F-FDG is potentially useful in identifying high-risk patients with aggressive neuroendocrine disease associated with a poor outcome. Although the use of new somatostatin analogues labeled with 68-Gallium for PET has significantly increased the sensitivity of NET imaging compared with single photon emission computed tomography and (18)F-FDG-PET, (18)F-FDG may retain an important role in managing patients with NETs owing to its high prognostic value and its higher sensitivity in delineating disease extent, especially in aggressive and high-grade tumors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (18)F-fluorodeoxyglucose (FDG); Imaging; Neuroendocrine tumors (NET); Positron emission tomography (PET); Prognosis

Mesh：

Substances：

Year:  2013        PMID： 25029933     DOI： 10.1016/j.cpet.2013.08.008

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  7 in total

Review 1.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

2.  Pancreatic Neuroendocrine Tumors: an Update.

Authors:  Alessandro Paniccia; Barish H Edil; Richard D Schulick
Journal:  Indian J Surg       Date:  2015-10-13       Impact factor: 0.656

3.  Nuclear medicine techniques in Merkel cell carcinoma: A case report and review of the literature.

Authors:  Nikolaos Kritikos; Dimitrios Priftakis; Stavros Stavrinides; Stefanos Kleanthous; Eleni Sarafianou
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

Review 4.  PET imaging in ectopic Cushing syndrome: a systematic review.

Authors:  Prasanna Santhanam; David Taieb; Luca Giovanella; Giorgio Treglia
Journal:  Endocrine       Date:  2015-07-25       Impact factor: 3.633

5.  Treatment of a mixed acinar-endocrine carcinoma with uptake on 68Gallium-DOTATOC positron emission tomography-computed tomography: A case report.

Authors:  Anneleen De Both; Marc De Man; Roberto Troisi; Hans Van Vlierberghe; Anne Hoorens; Karen Geboes
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

6.  Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group.

Authors:  Rachel P Riechelmann; Rui F Weschenfelder; Frederico P Costa; Aline Chaves Andrade; Alessandro Bersch Osvaldt; Ana Rosa P Quidute; Allan Dos Santos; Ana Amélia O Hoff; Brenda Gumz; Carlos Buchpiguel; Bruno S Vilhena Pereira; Delmar Muniz Lourenço Junior; Duilio Reis da Rocha Filho; Eduardo Antunes Fonseca; Eduardo Linhares Riello Mello; Fabio Ferrari Makdissi; Fabio Luiz Waechter; Francisco Cesar Carnevale; George B Coura-Filho; Gustavo Andrade de Paulo; Gustavo Colagiovanni Girotto; João Evangelista Bezerra Neto; João Glasberg; Jose Claudio Casali-da-Rocha; Juliana Florinda M Rego; Luciana Rodrigues de Meirelles; Ludhmila Hajjar; Marcos Menezes; Marcello D Bronstein; Marcelo Tatit Sapienza; Maria Candida Barisson Villares Fragoso; Maria Adelaide Albergaria Pereira; Milton Barros; Nora Manoukian Forones; Paulo Cezar Galvão do Amaral; Raphael Salles Scortegagna de Medeiros; Raphael L C Araujo; Regis Otaviano França Bezerra; Renata D'Alpino Peixoto; Samuel Aguiar; Ulysses Ribeiro; Tulio Pfiffer; Paulo M Hoff; Anelisa K Coutinho
Journal:  Ecancermedicalscience       Date:  2017-01-26

Review 7.  Role of Combined 68Ga DOTA-Peptides and 18F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Chalermrat Kaewput; Sobhan Vinjamuri
Journal:  Diagnostics (Basel)       Date:  2022-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.